| è´§å· | å“牌 | 产å“åç§° | è§„æ ¼ | 包装ã€å‚è€ƒä»·æ ¼ | |
| V729178 | MACKLIN | ç»´ç”Ÿç´ D3æ ‡å‡†æº¶æ¶² | 1mg/mL in ethanol | 1200å…ƒ/1ml; | 咨询 |
|
| D767938 | MACKLIN | ç»´ç”Ÿç´ D3溶液 | 100μg/mL in ethanol | 964å…ƒ/1ml; | 咨询 |
|
| C804669 | MACKLIN | ç»´ç”Ÿç´ D3 | 98% | 90å…ƒ/1g; 390å…ƒ/5g; 1932å…ƒ/25g; 7035å…ƒ/100g; | 咨询 |
储å˜ï¼š2~8°C 状æ€ï¼šç™½è‰²åˆ°æµ…黄色粉末 |
| C796970 | MACKLIN | ç»´ç”Ÿç´ D3 | 10mM in DMSO | 746å…ƒ/1ml; | 咨询 |
|
| 976277 | J&K | Cholecalciferol | 99% | 304元/1G; 1018元/5G; | 咨询 |
åŸºæœ¬ä¿¡æ¯ | 分åå¼ | C27H44O | | 分åé‡ | 384.64 | | 熔点 | 82-87 | | 比旋光度([α]20D) | +108 (C=0.5, EtOH) | | MDLç¼–ç | MFCD00078131 | | Beilstein | 2339331 | | Merck | 14,10019 | | EINECS ç¼–å· | 200-673-2 | | å˜å‚¨æ¡ä»¶ | Store at 2-8℃ | 一般æè¿° èƒ†é’™åŒ–é†‡æ¥æºäºŽé¥®é£Ÿæˆ–çš®è‚¤æŽ¥è§¦ç´«å¤–çº¿ã€‚å£æœç»´ç”Ÿç´ D3 å®¹æ˜“è¢«å¸æ”¶ï¼Œå¹¶å‚¨å˜åœ¨è„‚肪组织ä¸ã€‚èƒ†é’™åŒ–é†‡ä½œä¸ºä¸€ç§æ¿€ç´ å‰ä½“ï¼Œå› ä¸ºå®ƒéœ€è¦ä¸¤ä¸ªä»£è°¢é˜¶æ®µï¼šé¦–先是 25-羟胆钙化醇;然åŽåŠ å…¥ 1α,25-二羟胆钙化醇。一个å•ä½ï¼ˆU.S.P. 或国际)定义为 USP ç»´ç”Ÿç´ D å‚è€ƒæ ‡å‡†ä¸å«æœ‰ 0.025 μg ç»´ç”Ÿç´ D3 的活性。 生化/生ç†ä½œç”¨ ç»´ç”Ÿç´ D å€Ÿä»¥å‘æŒ¥ä½œç”¨çš„å—体是é…体ä¾èµ–æ€§è½¬å½•å› åè¶…å®¶æ—çš„æˆå‘˜ã€‚调控æ£å¸¸ç»†èƒžå’Œç™Œç»†èƒžçš„增殖和分化。对乳腺癌ã€ç»“è‚ ç™Œå’Œå‰åˆ—è…ºç™Œç»†èƒžå…·æœ‰æŠ—å¢žæ®–å’ŒæŠ—è½¬ç§»ä½œç”¨ã€‚è‚ å’Œéª¨éª¼ä¸çš„æ´»åŒ–ç»´ç”Ÿç´ D å—体维æŒç€é’™çš„叿”¶å’Œå¹³è¡¡ã€‚ 在慢性肾病ä¸ç»å¸¸è§‚å¯Ÿåˆ°ç»´ç”Ÿç´ D 的缺ä¹ã€‚ å®‰å…¨ä¿¡æ¯ | 图形或å±å®³æ ‡å¿— |   | | æç¤ºè¯ | Danger | | å±é™©è¯´æ˜Ž | H301 H311 H330 H372 | | 防范说明 | P260 P280 P284 P301+P310 P302+P350 P304+P340 P310 | | UNå·ç | 2811 | | å±é™©åˆ†ç±» | 6.1 | | 包装ç‰çº§ | II | | WGK | 2 | | RTECS | VS2900000 | | TSCA | 是 |
|
| C2150000 | | Cholecalciferol for system suitability | European Pharmacopoeia (EP) Reference Standard | 1556.7元/1 mL; | 咨询 |
产å“说明 一般æè¿° This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia. Cholecalciferol, also referred to as vitamin D3, promotes the absorption of calcium and phosphorus in the body to regulate bone growth. It is most commonly found in humans and animals and is produced in our skin when exposed to sunlight. It is used to treat and prevent bone disorders (such as rickets, osteomalacia). 应用 Cholecalciferol for system suitability may be used as an analytical reference standard for the determination of the analyte in pharmaceutical formulations by liquid chromatography. 生化/生ç†ä½œç”¨ ç»´ç”Ÿç´ D å€Ÿä»¥å‘æŒ¥ä½œç”¨çš„å—体是é…体ä¾èµ–æ€§è½¬å½•å› åè¶…å®¶æ—çš„æˆå‘˜ã€‚调控æ£å¸¸ç»†èƒžå’Œç™Œç»†èƒžçš„增殖和分化。对乳腺癌ã€ç»“è‚ ç™Œå’Œå‰åˆ—è…ºç™Œç»†èƒžå…·æœ‰æŠ—å¢žæ®–å’ŒæŠ—è½¬ç§»ä½œç”¨ã€‚è‚ å’Œéª¨éª¼ä¸çš„æ´»åŒ–ç»´ç”Ÿç´ D å—体维æŒç€é’™çš„叿”¶å’Œå¹³è¡¡ã€‚ 包装 Unit quantity: 1 mL. Subject to change. The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue. æ³¨æ„ Please find SDS provided by EDQM here.. 其他说明 Sales restrictions may apply. åŸºæœ¬ä¿¡æ¯ | ç»éªŒ(实验)分åå¼ | C27H44O | | 分åé‡ | 384.64 | | Beilstein | 2339331 | | MDLç¼–å· | MFCD00078131 | | PubChem化å¦ç‰©è´¨ç¼–å· | 329774967 | | NACRES | NA.24 |
äº§å“æ€§è´¨ | ç”Ÿç‰©æ¥æº | synthetic | | ç‰çº§ | pharmaceutical primary standard | | agency | EP | | å½¢å¼ | solid | | manufacturer/tradename | EDQM | | technique(s) | gas chromatography (GC): suitable liquid chromatography (LC): suitable | | mp | 83-86 ℃ (lit.) | | application(s) | pharmaceutical (small molecule) | | æ ¼å¼ | neat | | å‚¨å˜æ¸©åº¦ | −20℃ | | SMILES string | CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]([C@]1(C)CCC/2)([H])C2=C\C=C(C[C@@H](O)CC3)/C3=C | | InChI | 1S/C27H44O/c1-19(2)8-6-9-21(4)25-15-16-26-22(10-7-17-27(25,26)5)12-13-23-18-24(28)14-11-20(23)3/h12-13,19,21,24-26,28H,3,6-11,14-18H2,1-2,4-5H3/b22-12+,23-13-/t21-,24+,25-,26+,27-/m1/s1 | | InChI key | QYSXJUFSXHHAJI-YRZJJWOYSA-N | | Gene Information | human ... VDR(7421) |
å®‰å…¨ä¿¡æ¯ | 象形图 |   | | è¦ç¤ºç”¨è¯ï¼š | Danger | | å±é™©å£°æ˜Ž | H300 + H310 + H330 - H372 | | 预防措施声明 | P260 - P262 - P280 - P302 + P352 + P310 - P304 + P340 + P310 - P314 | | å±é™©åˆ†ç±» | Acute Tox. 2 Dermal - Acute Tox. 2 Inhalation - Acute Tox. 2 Oral - STOT RE 1 Oral | | 储å˜åˆ†ç±»ä»£ç | 6.1A - Combustible, acute toxic Cat. 1 and 2 / very toxic hazardous materials | | WGK | WGK 2 | | 闪点(F) | Not applicable | | 闪点(C) | Not applicable |
|
| C9756 | Sigma-Aldrich | Cholecalciferol | ≥98% (HPLC) | 766.86å…ƒ/1 G; 2936.86å…ƒ/5 G; | 咨询 |
产å“说明 一般æè¿° èƒ†é’™åŒ–é†‡æ¥æºäºŽé¥®é£Ÿæˆ–çš®è‚¤æŽ¥è§¦ç´«å¤–çº¿ã€‚å£æœç»´ç”Ÿç´ D3 å®¹æ˜“è¢«å¸æ”¶ï¼Œå¹¶å‚¨å˜åœ¨è„‚肪组织ä¸ã€‚ èƒ†é’™åŒ–é†‡ä½œä¸ºä¸€ç§æ¿€ç´ å‰ä½“ï¼Œå› ä¸ºå®ƒéœ€è¦ä¸¤ä¸ªä»£è°¢é˜¶æ®µï¼šé¦–先是 25-羟胆钙化醇;然åŽåŠ å…¥ 1α,25-二羟胆钙化醇。一个å•ä½(U.S.P. 或国际)定义为 USP ç»´ç”Ÿç´ D å‚è€ƒæ ‡å‡†ä¸å«æœ‰ 0.025 μg ç»´ç”Ÿç´ D3 的活性。 包装 1, 5 g in glass bottle 生化/生ç†ä½œç”¨ ç»´ç”Ÿç´ D å€Ÿä»¥å‘æŒ¥ä½œç”¨çš„å—体是é…体ä¾èµ–æ€§è½¬å½•å› åè¶…å®¶æ—çš„æˆå‘˜ã€‚调控æ£å¸¸ç»†èƒžå’Œç™Œç»†èƒžçš„增殖和分化。对乳腺癌ã€ç»“è‚ ç™Œå’Œå‰åˆ—è…ºç™Œç»†èƒžå…·æœ‰æŠ—å¢žæ®–å’ŒæŠ—è½¬ç§»ä½œç”¨ã€‚è‚ å’Œéª¨éª¼ä¸çš„æ´»åŒ–ç»´ç”Ÿç´ D å—体维æŒç€é’™çš„叿”¶å’Œå¹³è¡¡ã€‚ 在慢性肾病ä¸ç»å¸¸è§‚å¯Ÿåˆ°ç»´ç”Ÿç´ D 的缺ä¹ã€‚ 储å˜åŠç¨³å®šæ€§ 胆钙化醇 C9756 在氩气下包装。如果未开å°å‚¨å˜åœ¨ 2-8℃ 且é¿å…‰ï¼Œåˆ™æœ¬äº§å“å¯ä»¥ç¨³å®šä¿å˜è‡³å°‘三年。未使用的部分应储å˜åœ¨æ°®æ°”或氩气下。在冰箱温度下,在棕色-抽真空安瓿ä¸å‚¨å˜ä¸€å¹´åŽï¼Œå˜è´¨å¯å¿½ç•¥ä¸è®¡ã€‚å®ƒä¼šåœ¨å‡ å¤©å†…è¢«æ½®æ¹¿çš„ç©ºæ°”æ°§åŒ–å’Œçæ´»ã€‚ åŸºæœ¬ä¿¡æ¯ | ç»éªŒ(实验)分åå¼ | C27H44O | | 分åé‡ | 384.64 | | Beilstein | 2339331 | | EC å· | 200-673-2 | | MDLç¼–å· | MFCD00078131 | | eCl@ss | 34058003 | | PubChem化å¦ç‰©è´¨ç¼–å· | 24893192 | | NACRES | NA.26 |
äº§å“æ€§è´¨ | è´¨é‡æ°´å¹³ | 200 | | ç”Ÿç‰©æ¥æº | synthetic (organic) | | 测定 | ≥98% (HPLC) | | å½¢å¼ | powder | | technique(s) | HPLC: suitable | | 颜色 | white to off-white | | mp | 83-86 ℃ (lit.) | | å‚¨å˜æ¸©åº¦ | 2-8℃ | | SMILES string | CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]([C@]1(C)CCC/2)([H])C2=C\C=C(C[C@@H](O)CC3)/C3=C | | InChI | 1S/C27H44O/c1-19(2)8-6-9-21(4)25-15-16-26-22(10-7-17-27(25,26)5)12-13-23-18-24(28)14-11-20(23)3/h12-13,19,21,24-26,28H,3,6-11,14-18H2,1-2,4-5H3/b22-12+,23-13-/t21-,24+,25-,26+,27-/m1/s1 | | InChI key | QYSXJUFSXHHAJI-YRZJJWOYSA-N | | Gene Information | human ... VDR(7421) |
å®‰å…¨ä¿¡æ¯ | 象形图 |   | | è¦ç¤ºç”¨è¯ï¼š | Danger | | å±é™©å£°æ˜Ž | H300 + H310 + H330 - H372 | | 预防措施声明 | P260 - P262 - P280 - P302 + P352 + P310 - P304 + P340 + P310 - P314 | | å±é™©åˆ†ç±» | Acute Tox. 2 Dermal - Acute Tox. 2 Inhalation - Acute Tox. 2 Oral - STOT RE 1 Oral | | 储å˜åˆ†ç±»ä»£ç | 6.1A - Combustible, acute toxic Cat. 1 and 2 / very toxic hazardous materials | | WGK | WGK 2 | | 闪点(F) | Not applicable | | 闪点(C) | Not applicable | | 个人防护装备 | Eyeshields, Faceshields, Gloves, type P1 (EN143) respirator filter, type P3 (EN 143) respirator cartridges |
|
| C2100000 | | Cholecalciferol | European Pharmacopoeia (EP) Reference Standard | 1572.27元/ ; | 咨询 |
产å“说明 一般æè¿° æœ¬å“æŒ‰çŽ°è¡Œè¯å…¸è§„å®šäº¤ä»˜ã€‚æ‰€æœ‰ä¸ºæ”¯æŒæœ¬äº§å“而æä¾›çš„ä¿¡æ¯ï¼ŒåŒ…括SDS和任何产å“ä¿¡æ¯å•å‡ç”±è¯å…¸é¢å‘机构制定并å‘布。如需进一æ¥ä¿¡æ¯å’Œæ”¯æŒï¼Œè¯·è®¿é—®çŽ°è¡Œè¯å…¸ç½‘站。胆钙化醇是一ç§è„‚æº¶æ€§ç»´ç”Ÿç´ ï¼Œå•†ä¸šä¸Šç”¨äºŽç»´ç”Ÿç´ è¡¥å……å‰‚å’Œæ€é¼ 剂。它å¯é€šè¿‡æš´éœ²äºŽé˜³å…‰ç›´æŽ¥åˆæˆæˆ–通过æ£å¸¸çš„膳食摄å–。 应用 胆钙化醇å¯ä½œä¸ºåˆ†æžå‚è€ƒæ ‡å‡†å“ï¼Œé€šè¿‡éžæ°´å相高效液相色谱技术定é‡åˆ†æžèƒ¶å›Šä¸çš„分æžç‰©ã€‚ 生化/生ç†ä½œç”¨ ç»´ç”Ÿç´ D å€Ÿä»¥å‘æŒ¥ä½œç”¨çš„å—体是é…体ä¾èµ–æ€§è½¬å½•å› åè¶…å®¶æ—çš„æˆå‘˜ã€‚调控æ£å¸¸ç»†èƒžå’Œç™Œç»†èƒžçš„增殖和分化。对乳腺癌ã€ç»“è‚ ç™Œå’Œå‰åˆ—è…ºç™Œç»†èƒžå…·æœ‰æŠ—å¢žæ®–å’ŒæŠ—è½¬ç§»ä½œç”¨ã€‚è‚ å’Œéª¨éª¼ä¸çš„æ´»åŒ–ç»´ç”Ÿç´ D å—体维æŒç€é’™çš„叿”¶å’Œå¹³è¡¡ã€‚ 包装 Unit quantity: 260 mg. Subject to change. The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue. æ³¨æ„ è¯·å‚è§ ç”±EDQMæä¾›çš„SDS。. 其他说明 å¯èƒ½é€‚用相应的销售é™åˆ¶ã€‚ åŸºæœ¬ä¿¡æ¯ | ç»éªŒ(实验)分åå¼ | C27H44O | | 分åé‡ | 384.64 | | Beilstein | 2339331 | | MDLç¼–å· | MFCD00078131 | | PubChem化å¦ç‰©è´¨ç¼–å· | 329774925 | | NACRES | NA.24 |
äº§å“æ€§è´¨ | ç”Ÿç‰©æ¥æº | synthetic | | ç‰çº§ | pharmaceutical primary standard | | agency | EP | | å½¢å¼ | solid | | manufacturer/tradename | EDQM | | technique(s) | gas chromatography (GC): suitable liquid chromatography (LC): suitable | | mp | 83-86 ℃ (lit.) | | application(s) | pharmaceutical (small molecule) | | æ ¼å¼ | neat | | å‚¨å˜æ¸©åº¦ | −20℃ | | SMILES string | CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]([C@]1(C)CCC/2)([H])C2=C\C=C(C[C@@H](O)CC3)/C3=C | | InChI | 1S/C27H44O/c1-19(2)8-6-9-21(4)25-15-16-26-22(10-7-17-27(25,26)5)12-13-23-18-24(28)14-11-20(23)3/h12-13,19,21,24-26,28H,3,6-11,14-18H2,1-2,4-5H3/b22-12+,23-13-/t21-,24+,25-,26+,27-/m1/s1 | | InChI key | QYSXJUFSXHHAJI-YRZJJWOYSA-N | | Gene Information | human ... VDR(7421) |
å®‰å…¨ä¿¡æ¯ | 象形图 |   | | è¦ç¤ºç”¨è¯ï¼š | Danger | | å±é™©å£°æ˜Ž | H300 + H310 + H330 - H372 | | 预防措施声明 | P260 - P262 - P280 - P302 + P352 + P310 - P304 + P340 + P310 - P314 | | å±é™©åˆ†ç±» | Acute Tox. 2 Dermal - Acute Tox. 2 Inhalation - Acute Tox. 2 Oral - STOT RE 1 Oral | | 储å˜åˆ†ç±»ä»£ç | 6.1A - Combustible, acute toxic Cat. 1 and 2 / very toxic hazardous materials | | WGK | WGK 2 | | 闪点(F) | Not applicable | | 闪点(C) | Not applicable |
|
| C9774 | Sigma-Aldrich | Cholecalciferol | analytical standard | 1189.47元/1 AMP; 4593.8元/5 AMP; | 咨询 |
产å“说明 一般æè¿° Cholecalciferol, also called vitamin D3, promotes the absorption of calcium and phosphorus in the body to regulate bone growth. It is most commonly found in humans and animals and is produced in our skin when exposed to sunlight. It is used to treat and prevent bone disorders (such as rickets, osteomalacia). 应用 Cholecalciferol has been used as an internal standard in high-performance liquid chromatography (HPLC) to analyze serum vitamin D levels. It has also been used as a standard in liquid chromatography-electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS) to quantify vitamin D3 in sunflower oil. Cholecalciferol may be used as an analytical reference standard for the determination of the analyte in pharmaceutical formulations by liquid chromatography. 包装 1, 5 amp in ampule Packaged in flame-sealed ampules under Argon 生化/生ç†ä½œç”¨ ç»´ç”Ÿç´ D å€Ÿä»¥å‘æŒ¥ä½œç”¨çš„å—体是é…体ä¾èµ–æ€§è½¬å½•å› åè¶…å®¶æ—çš„æˆå‘˜ã€‚调控æ£å¸¸ç»†èƒžå’Œç™Œç»†èƒžçš„增殖和分化。对乳腺癌ã€ç»“è‚ ç™Œå’Œå‰åˆ—è…ºç™Œç»†èƒžå…·æœ‰æŠ—å¢žæ®–å’ŒæŠ—è½¬ç§»ä½œç”¨ã€‚è‚ å’Œéª¨éª¼ä¸çš„æ´»åŒ–ç»´ç”Ÿç´ D å—体维æŒç€é’™çš„叿”¶å’Œå¹³è¡¡ã€‚ Cholecalciferol is sourced either through the diet or exposing skin to ultraviolet rays. Oral administration of vitamin D3 is readily absorbed and is stored in adipose tissue. Deficiency of vitamin D is often observed in chronic kidney disease. åŸºæœ¬ä¿¡æ¯ | ç»éªŒ(实验)分åå¼ | C27H44O | | 分åé‡ | 384.64 | | Beilstein | 2339331 | | EC å· | 200-673-2 | | MDLç¼–å· | MFCD00078131 | | eCl@ss | 34058003 | | PubChem化å¦ç‰©è´¨ç¼–å· | 24893197 | | NACRES | NA.77 |
äº§å“æ€§è´¨ | è´¨é‡æ°´å¹³ | 200 | | ç”Ÿç‰©æ¥æº | synthetic (organic - wool) | | ç‰çº§ | analytical standard | | 测定 | ≥97.0% | | å½¢å¼ | crystalline | | 包装 | pkg of 250 mg | | 颜色 | white | | mp | 83-86 ℃ (lit.) | | å‚¨å˜æ¸©åº¦ | 2-8℃ | | SMILES string | CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]([C@]1(C)CCC/2)([H])C2=C\C=C(C[C@@H](O)CC3)/C3=C | | InChI | 1S/C27H44O/c1-19(2)8-6-9-21(4)25-15-16-26-22(10-7-17-27(25,26)5)12-13-23-18-24(28)14-11-20(23)3/h12-13,19,21,24-26,28H,3,6-11,14-18H2,1-2,4-5H3/b22-12+,23-13-/t21-,24+,25-,26+,27-/m1/s1 | | InChI key | QYSXJUFSXHHAJI-YRZJJWOYSA-N | | Gene Information | human ... VDR(7421) |
å®‰å…¨ä¿¡æ¯ | 象形图 |   | | è¦ç¤ºç”¨è¯ï¼š | Danger | | å±é™©å£°æ˜Ž | H300 + H310 + H330 - H372 | | 预防措施声明 | P260 - P262 - P280 - P302 + P352 + P310 - P304 + P340 + P310 - P314 | | å±é™©åˆ†ç±» | Acute Tox. 2 Dermal - Acute Tox. 2 Inhalation - Acute Tox. 2 Oral - STOT RE 1 Oral | | 储å˜åˆ†ç±»ä»£ç | 6.1A - Combustible, acute toxic Cat. 1 and 2 / very toxic hazardous materials | | WGK | WGK 2 | | 闪点(F) | Not applicable | | 闪点(C) | Not applicable | | 个人防护装备 | Eyeshields, Faceshields, Gloves, type P1 (EN143) respirator filter, type P3 (EN 143) respirator cartridges |
|
| C1357 | Sigma-Aldrich | Cholecalciferol | meets USP testing specifications | 595.59元/250 MG; 970.43元/1 G; | 咨询 |
产å“说明 一般æè¿° 胆钙化醇(ç»´ç”Ÿç´ D3)是一ç§åœ¨çš®è‚¤ä¸äº§ç”Ÿçš„脂溶性类固醇。 应用 胆钙化醇已被用于: - 诱导å°é¼ 动脉ä¸è†œé’™åŒ– (arterial medial calcification,AMC)
- ç ”ç©¶å…¶åœ¨è‚¥èƒ–å’Œèƒ°å²›ç´ æŠµæŠ—å°é¼ 模型ä¸å¯¹è¡€ç®¡é’™åŒ–(VC)相关血管é‡å¡‘的影å“(ob / obå°é¼ )
- ç ”ç©¶å…¶å¯¹å•层培养物ä¸RWPE2-W99细胞锚定ä¾èµ–性生长的影å“
包装 25 g in glass bottle 1 g in ampule 250 mg in ampule 生化/生ç†ä½œç”¨ ç»´ç”Ÿç´ D å€Ÿä»¥å‘æŒ¥ä½œç”¨çš„å—体是é…体ä¾èµ–æ€§è½¬å½•å› åè¶…å®¶æ—çš„æˆå‘˜ã€‚调控æ£å¸¸ç»†èƒžå’Œç™Œç»†èƒžçš„增殖和分化。对乳腺癌ã€ç»“è‚ ç™Œå’Œå‰åˆ—è…ºç™Œç»†èƒžå…·æœ‰æŠ—å¢žæ®–å’ŒæŠ—è½¬ç§»ä½œç”¨ã€‚è‚ å’Œéª¨éª¼ä¸çš„æ´»åŒ–ç»´ç”Ÿç´ D å—体维æŒç€é’™çš„叿”¶å’Œå¹³è¡¡ã€‚ åŸºæœ¬ä¿¡æ¯ | ç»éªŒ(实验)分åå¼ | C27H44O | | 分åé‡ | 384.64 | | Beilstein | 2339331 | | EC å· | 200-673-2 | | MDLç¼–å· | MFCD00078131 | | eCl@ss | 34058003 | | PubChem化å¦ç‰©è´¨ç¼–å· | 24892404 | | NACRES | NA.21 |
äº§å“æ€§è´¨ | è´¨é‡æ°´å¹³ | 200 | | agency | USP/NF meets USP testing specifications | | 测定 | 97.0-103.0% | | å½¢å¼ | crystalline | | 颜色 | white | | mp | 83-86 ℃ (lit.) | | application(s) | pharmaceutical (small molecule) | | å‚¨å˜æ¸©åº¦ | 2-8℃ | | SMILES string | CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]([C@]1(C)CCC/2)([H])C2=C\C=C(C[C@@H](O)CC3)/C3=C | | InChI | 1S/C27H44O/c1-19(2)8-6-9-21(4)25-15-16-26-22(10-7-17-27(25,26)5)12-13-23-18-24(28)14-11-20(23)3/h12-13,19,21,24-26,28H,3,6-11,14-18H2,1-2,4-5H3/b22-12+,23-13-/t21-,24+,25-,26+,27-/m1/s1 | | InChI key | QYSXJUFSXHHAJI-YRZJJWOYSA-N | | Gene Information | human ... VDR(7421) |
å®‰å…¨ä¿¡æ¯ | 象形图 |   | | è¦ç¤ºç”¨è¯ï¼š | Danger | | å±é™©å£°æ˜Ž | H300 + H310 + H330 - H372 | | 预防措施声明 | P260 - P262 - P280 - P302 + P352 + P310 - P304 + P340 + P310 - P314 | | å±é™©åˆ†ç±» | Acute Tox. 2 Dermal - Acute Tox. 2 Inhalation - Acute Tox. 2 Oral - STOT RE 1 Oral | | 储å˜åˆ†ç±»ä»£ç | 6.1A - Combustible, acute toxic Cat. 1 and 2 / very toxic hazardous materials | | WGK | WGK 2 | | 闪点(F) | Not applicable | | 闪点(C) | Not applicable | | 个人防护装备 | Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges |
|
| 1131009 | USP | Cholecalciferol | United States Pharmacopeia (USP) Reference Standard | 3365.61元/5 X 30 MG; | 咨询 |
产å“说明 一般æè¿° æœ¬äº§å“æŒ‰ç…§çŽ°è¡Œè¯å…¸è¦æ±‚æä¾›å’ŒæŒ‡å®šã€‚æ‰€æœ‰ä¸ºæ”¯æŒæœ¬äº§å“而æä¾›çš„ä¿¡æ¯ï¼ŒåŒ…括 SDS 和任何产å“ä¿¡æ¯å°å†Œå,å‡ç”±è¯å…¸é¢å‘机构制定和å‘布。如需进一æ¥çš„ä¿¡æ¯å’Œæ”¯æŒï¼Œè¯·è®¿é—®çŽ°è¡Œè¯å…¸ç½‘站。如需进一æ¥ä¿¡æ¯å’Œæ”¯æŒï¼Œè¯·è®¿é—®çŽ°è¡Œè¯å…¸ç½‘站。 生化/生ç†ä½œç”¨ ç»´ç”Ÿç´ D å€Ÿä»¥å‘æŒ¥ä½œç”¨çš„å—体是é…体ä¾èµ–æ€§è½¬å½•å› åè¶…å®¶æ—çš„æˆå‘˜ã€‚调控æ£å¸¸ç»†èƒžå’Œç™Œç»†èƒžçš„增殖和分化。对乳腺癌ã€ç»“è‚ ç™Œå’Œå‰åˆ—è…ºç™Œç»†èƒžå…·æœ‰æŠ—å¢žæ®–å’ŒæŠ—è½¬ç§»ä½œç”¨ã€‚è‚ å’Œéª¨éª¼ä¸çš„æ´»åŒ–ç»´ç”Ÿç´ D å—体维æŒç€é’™çš„叿”¶å’Œå¹³è¡¡ã€‚ 分æžè¯´æ˜Ž 这些产å“仅供测试和分æžä½¿ç”¨ã€‚它们ä¸é€‚用于人类或动物的给è¯ï¼Œä¸å¯ç”¨äºŽè¯Šæ–ã€æ²»ç–—或治愈任何疾病。 其他说明 USPé¢å¸ƒçš„SDS请点击æ¤å¤„。 å¯èƒ½é€‚用相应的销售é™åˆ¶ã€‚ åŸºæœ¬ä¿¡æ¯ | ç»éªŒ(实验)分åå¼ | C27H44O | | 分åé‡ | 384.64 | | Beilstein | 2339331 | | MDLç¼–å· | MFCD00078131 | | PubChem化å¦ç‰©è´¨ç¼–å· | 329749357 |
äº§å“æ€§è´¨ | ç‰çº§ | pharmaceutical primary standard | | manufacturer/tradename | USP | | mp | 83-86 ℃ (lit.) | | application(s) | pharmaceutical (small molecule) | | æ ¼å¼ | neat | | å‚¨å˜æ¸©åº¦ | −20℃ | | SMILES string | CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]([C@]1(C)CCC/2)([H])C2=C\C=C(C[C@@H](O)CC3)/C3=C | | InChI | 1S/C27H44O/c1-19(2)8-6-9-21(4)25-15-16-26-22(10-7-17-27(25,26)5)12-13-23-18-24(28)14-11-20(23)3/h12-13,19,21,24-26,28H,3,6-11,14-18H2,1-2,4-5H3/b22-12+,23-13-/t21-,24+,25-,26+,27-/m1/s1 | | InChI key | QYSXJUFSXHHAJI-YRZJJWOYSA-N | | Gene Information | human ... VDR(7421) |
å®‰å…¨ä¿¡æ¯ | 象形图 |   | | è¦ç¤ºç”¨è¯ï¼š | Danger | | å±é™©å£°æ˜Ž | H300 + H310 + H330 - H372 | | 预防措施声明 | P260 - P262 - P280 - P302 + P352 + P310 - P304 + P340 + P310 - P314 | | å±é™©åˆ†ç±» | Acute Tox. 2 Dermal - Acute Tox. 2 Inhalation - Acute Tox. 2 Oral - STOT RE 1 Oral | | 储å˜åˆ†ç±»ä»£ç | 6.1A - Combustible, acute toxic Cat. 1 and 2 / very toxic hazardous materials | | WGK | WGK 2 | | 闪点(F) | Not applicable | | 闪点(C) | Not applicable |
|
| 47763 | Supelco | Cholecalciferol (D3) | analytical standard | 471.31元/100 MG; | 咨询 |
产å“说明 一般æè¿° 胆钙化醇(D3)是一ç§è„‚æº¶æ€§ç»´ç”Ÿç´ ï¼Œå±žäºŽç»´ç”Ÿç´ D的一ç§å½¢å¼ï¼Œå¯åœ¨æš´éœ²äºŽå¤ªé˜³å…‰ç´«å¤–线(UV)下的人皮肤ä¸åˆæˆï¼Œæˆ–从食物ä¸èŽ·å–。它是维æŒäººä½“æ£å¸¸é’™ä»£è°¢çš„必需æˆåˆ†ã€‚ 应用 有关åˆé€‚的仪器技术的更多信æ¯ï¼Œè¯·å‚阅产å“′的分æžè¯ä¹¦ã€‚è”系技术æœåŠ¡éƒ¨ä»¥èŽ·å¾—è¿›ä¸€æ¥æ”¯æŒã€‚ 胆钙化醇(D3)å¯ä½œä¸ºåˆ†æžæ ‡å‡†å“,通过ä¸åŒçš„色谱技术对ä¸åŒé£Ÿå“基质ä¸çš„分æžç‰©è¿›è¡Œå®šé‡ã€‚ 生化/生ç†ä½œç”¨ ç»´ç”Ÿç´ D å€Ÿä»¥å‘æŒ¥ä½œç”¨çš„å—体是é…体ä¾èµ–æ€§è½¬å½•å› åè¶…å®¶æ—çš„æˆå‘˜ã€‚调控æ£å¸¸ç»†èƒžå’Œç™Œç»†èƒžçš„增殖和分化。对乳腺癌ã€ç»“è‚ ç™Œå’Œå‰åˆ—è…ºç™Œç»†èƒžå…·æœ‰æŠ—å¢žæ®–å’ŒæŠ—è½¬ç§»ä½œç”¨ã€‚è‚ å’Œéª¨éª¼ä¸çš„æ´»åŒ–ç»´ç”Ÿç´ D å—体维æŒç€é’™çš„叿”¶å’Œå¹³è¡¡ã€‚ åŸºæœ¬ä¿¡æ¯ | ç»éªŒ(实验)分åå¼ | C27H44O | | 分åé‡ | 384.64 | | Beilstein | 2339331 | | EC å· | 200-673-2 | | MDLç¼–å· | MFCD00078131 | | PubChem化å¦ç‰©è´¨ç¼–å· | 24871395 |
äº§å“æ€§è´¨ | è´¨é‡æ°´å¹³ | 100 | | ç‰çº§ | analytical standard | | å½¢å¼ | solid | | CofA | current certificate can be downloaded | | 特点 | standard type fat soluble vitamin | | 包装 | ampule of 100 mg | | technique(s) | HPLC: suitable gas chromatography (GC): suitable | | 颜色 | white | | mp | 83-86 ℃ (lit.) | | application(s) | food and beverages | | æ ¼å¼ | neat | | å‚¨å˜æ¸©åº¦ | 2-8℃ | | SMILES string | CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]([C@]1(C)CCC/2)([H])C2=C\C=C(C[C@@H](O)CC3)/C3=C | | InChI | 1S/C27H44O/c1-19(2)8-6-9-21(4)25-15-16-26-22(10-7-17-27(25,26)5)12-13-23-18-24(28)14-11-20(23)3/h12-13,19,21,24-26,28H,3,6-11,14-18H2,1-2,4-5H3/b22-12+,23-13-/t21-,24+,25-,26+,27-/m1/s1 | | InChI key | QYSXJUFSXHHAJI-YRZJJWOYSA-N | | Gene Information | human ... VDR(7421) |
å®‰å…¨ä¿¡æ¯ | 象形图 |   | | è¦ç¤ºç”¨è¯ï¼š | Danger | | å±é™©å£°æ˜Ž | H300 + H310 + H330 - H372 | | 预防措施声明 | P260 - P262 - P280 - P302 + P352 + P310 - P304 + P340 + P310 - P314 | | å±é™©åˆ†ç±» | Acute Tox. 2 Dermal - Acute Tox. 2 Inhalation - Acute Tox. 2 Oral - STOT RE 1 Oral | | 储å˜åˆ†ç±»ä»£ç | 6.1A - Combustible, acute toxic Cat. 1 and 2 / very toxic hazardous materials | | WGK | WGK 2 | | 闪点(F) | Not applicable | | 闪点(C) | Not applicable | | 个人防护装备 | Eyeshields, Faceshields, Gloves, type P1 (EN143) respirator filter, type P3 (EN 143) respirator cartridges |
|
| PHR1237 | Supelco | Cholecalciferol (Vitamin D3) | Pharmaceutical Secondary Standard; Certified Reference Material | 1631.06元/500 MG; | 咨询 |
产å“说明 一般æè¿° ç”¨äºŽè´¨é‡æŽ§åˆ¶çš„åˆ¶è¯äºŒçº§æ ‡å‡†å“为制è¯å®žéªŒå®¤å’Œåˆ¶é€ å•†å†…éƒ¨åˆ¶å¤‡å·¥ä½œæ ‡å‡†å“æä¾›äº†ä¸€ç§æ–¹ä¾¿ã€é«˜æ€§ä»·æ¯”的替代方案。 胆钙化醇(ç»´ç”Ÿç´ D3)是一ç§è„‚æº¶æ€§ç»´ç”Ÿç´ ï¼Œèƒ½ä½“çŽ°å¯¹éª¨éª¼å’Œéª¨éª¼å¤–æ•ˆåº”ã€‚éª¨éª¼æ•ˆåº”å¢žå¼ºéª¨éª¼å¥åº·ï¼Œè€Œéª¨éª¼å¤–效应则涉åŠå…疫系统ã€è®¤çŸ¥ç³»ç»Ÿã€å¿ƒè¡€ç®¡ç³»ç»Ÿç‰ã€‚ 应用 胆钙化醇(ç»´ç”Ÿç´ D3)å¯ä½œä¸ºåˆ¶è¯å‚è€ƒæ ‡å‡†å“,通过å„ç§è‰²è°±æŠ€æœ¯æµ‹å®šé£Ÿå“ã€ç§åã€è¡€æ¸…æ ·æœ¬å’Œåˆ¶è¯åˆ¶å‰‚ä¸çš„分æžç‰©ã€‚ è¿™äº›äºŒçº§æ ‡å‡†å“æ˜¯ç»è¿‡æ£€éªŒçš„è®¤è¯æ ‡å‡†ç‰©è´¨(CRM)。它们适用于多ç§åˆ†æžåº”用,包括但ä¸é™äºŽè¯ç‰©é‡Šæ”¾æµ‹è¯•ã€è¯ç‰©çš„定性和定é‡åˆ†æžæ–¹æ³•å¼€å‘ã€é£Ÿå“å’Œé¥®æ–™è´¨é‡æŽ§åˆ¶æ£€æµ‹ä»¥åŠå…¶ä»–æ ‡å®šåº”ç”¨ã€‚ 生化/生ç†ä½œç”¨ ç»´ç”Ÿç´ D å€Ÿä»¥å‘æŒ¥ä½œç”¨çš„å—体是é…体ä¾èµ–æ€§è½¬å½•å› åè¶…å®¶æ—çš„æˆå‘˜ã€‚调控æ£å¸¸ç»†èƒžå’Œç™Œç»†èƒžçš„增殖和分化。对乳腺癌ã€ç»“è‚ ç™Œå’Œå‰åˆ—è…ºç™Œç»†èƒžå…·æœ‰æŠ—å¢žæ®–å’ŒæŠ—è½¬ç§»ä½œç”¨ã€‚è‚ å’Œéª¨éª¼ä¸çš„æ´»åŒ–ç»´ç”Ÿç´ D å—体维æŒç€é’™çš„叿”¶å’Œå¹³è¡¡ã€‚ 分æžè¯´æ˜Ž è¿™äº›äºŒçº§æ ‡å‡†å“为USPã€EP(PhEur)å’ŒBPç‰ä¸»è¦æ ‡å‡†å“æä¾›äº†å¤šç§å¯è¿½æº¯æ€§ã€‚ 其他说明 该认è¯å‚考物质(CRM)æ ¹æ®ISO 17034 å’Œ ISO/IEC 17025进行生产和认è¯ã€‚有关æ¤CRM使用的所有信æ¯å‡å¯åœ¨åˆ†æžè¯ä¹¦ä¸Šæ‰¾åˆ°ã€‚ 附注 欲查看æ¤ç‰©è´¨çš„分æžè¯ä¹¦æ ·æœ¬ï¼Œè¯·åœ¨ä¸‹é¢çš„å¯¹è¯æ¡†ä¸è¾“å…¥LRAC0270。其仅是一个示例è¯ä¹¦ï¼Œå¯èƒ½ä¸æ˜¯æ‚¨æ‰€æ”¶åˆ°çš„æ‰¹æ¬¡ã€‚ åŸºæœ¬ä¿¡æ¯ | ç»éªŒ(实验)分åå¼ | C27H44O | | 分åé‡ | 384.64 | | Beilstein | 2339331 | | EC å· | 200-673-2 | | MDLç¼–å· | MFCD00078131 | | PubChem化å¦ç‰©è´¨ç¼–å· | 329823242 | | NACRES | NA.24 |
äº§å“æ€§è´¨ | è´¨é‡æ°´å¹³ | 300 | | ç‰çº§ | certified reference material pharmaceutical secondary standard | | å½¢å¼ | solid | | CofA | current certificate can be downloaded | | technique(s) | HPLC: suitable gas chromatography (GC): suitable | | mp | 83-86 ℃ (lit.) | | application(s) | food and beverages | | æ ¼å¼ | neat | | è¯å…¸å¯è¿½æº¯æ€§ | traceable to BP 787 traceable to PhEur C2100000 traceable to USP 1131009 | | å‚¨å˜æ¸©åº¦ | -10 to -25℃ | | SMILES string | CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]([C@]1(C)CCC/2)([H])C2=C\C=C(C[C@@H](O)CC3)/C3=C | | InChI | 1S/C27H44O/c1-19(2)8-6-9-21(4)25-15-16-26-22(10-7-17-27(25,26)5)12-13-23-18-24(28)14-11-20(23)3/h12-13,19,21,24-26,28H,3,6-11,14-18H2,1-2,4-5H3/b22-12+,23-13-/t21-,24+,25-,26+,27-/m1/s1 | | InChI key | QYSXJUFSXHHAJI-YRZJJWOYSA-N | | Gene Information | human ... VDR(7421) |
å®‰å…¨ä¿¡æ¯ | 象形图 |   | | è¦ç¤ºç”¨è¯ï¼š | Danger | | å±é™©å£°æ˜Ž | H300 + H310 + H330 - H372 | | 预防措施声明 | P260 - P262 - P280 - P302 + P352 + P310 - P304 + P340 + P310 - P314 | | å±é™©åˆ†ç±» | Acute Tox. 2 Dermal - Acute Tox. 2 Inhalation - Acute Tox. 2 Oral - STOT RE 1 Oral | | 储å˜åˆ†ç±»ä»£ç | 6.1A - Combustible, acute toxic Cat. 1 and 2 / very toxic hazardous materials | | WGK | WGK 2 | | 闪点(F) | Not applicable | | 闪点(C) | Not applicable |
|
| BP787 | | colecalciferol | British Pharmacopoeia (BP) Reference Standard | 858.61元/500 MG; | 咨询 |
产å“说明 一般æè¿° This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia. Colecalciferol is a fat soluble vitamin, which participates in the calcium and phosphate metabolism. It is sourced either through the diet or by exposing skin to ultraviolet rays. Oral administration of vitamin D3 is readily absorbed and is stored in adipose tissue. 生化/生ç†ä½œç”¨ ç»´ç”Ÿç´ D å€Ÿä»¥å‘æŒ¥ä½œç”¨çš„å—体是é…体ä¾èµ–æ€§è½¬å½•å› åè¶…å®¶æ—çš„æˆå‘˜ã€‚调控æ£å¸¸ç»†èƒžå’Œç™Œç»†èƒžçš„增殖和分化。对乳腺癌ã€ç»“è‚ ç™Œå’Œå‰åˆ—è…ºç™Œç»†èƒžå…·æœ‰æŠ—å¢žæ®–å’ŒæŠ—è½¬ç§»ä½œç”¨ã€‚è‚ å’Œéª¨éª¼ä¸çš„æ´»åŒ–ç»´ç”Ÿç´ D å—体维æŒç€é’™çš„叿”¶å’Œå¹³è¡¡ã€‚ 包装 Unit quantity: 500 mg. Subject to change. The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity please visit British Pharmacopoeia 其他说明 Sales restrictions may apply. åŸºæœ¬ä¿¡æ¯ | ç»éªŒ(实验)分åå¼ | C27H44O | | 分åé‡ | 384.64 | | Beilstein | 2339331 | | EC å· | 200-673-2 | | MDLç¼–å· | MFCD00078131 | | NACRES | NA.24 |
äº§å“æ€§è´¨ | ç‰çº§ | pharmaceutical primary standard | | manufacturer/tradename | BP | | 颜色 | white | | mp | 83-86 ℃ (lit.) | | æ ¼å¼ | neat | | å‚¨å˜æ¸©åº¦ | −20℃ | | SMILES string | CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]([C@]1(C)CCC/2)([H])C2=C\C=C(C[C@@H](O)CC3)/C3=C | | InChI | 1S/C27H44O/c1-19(2)8-6-9-21(4)25-15-16-26-22(10-7-17-27(25,26)5)12-13-23-18-24(28)14-11-20(23)3/h12-13,19,21,24-26,28H,3,6-11,14-18H2,1-2,4-5H3/b22-12+,23-13-/t21-,24+,25-,26+,27-/m1/s1 | | InChI key | QYSXJUFSXHHAJI-YRZJJWOYSA-N | | Gene Information | human ... VDR(7421) |
å®‰å…¨ä¿¡æ¯ | 象形图 |   | | è¦ç¤ºç”¨è¯ï¼š | Danger | | å±é™©å£°æ˜Ž | H300 + H310 + H330 - H372 | | 预防措施声明 | P260 - P262 - P280 - P302 + P352 + P310 - P304 + P340 + P310 - P314 | | å±é™©åˆ†ç±» | Acute Tox. 2 Dermal - Acute Tox. 2 Inhalation - Acute Tox. 2 Oral - STOT RE 1 Oral | | 储å˜åˆ†ç±»ä»£ç | 6.1A - Combustible, acute toxic Cat. 1 and 2 / very toxic hazardous materials | | WGK | WGK 2 | | 闪点(F) | Not applicable | | 闪点(C) | Not applicable |
|
| VIT-013N | AccuStandard | Vitamin D3 | | 428元/100mg; | 咨询 |
| Cholecalciferol | ç»´ç”Ÿç´ D3 | 67-97-0 | |
|